Rhizosphere competent Pseudomonas indoloxydans (F3-47) as a plant growth promoter and enhancer of Zea mays L. under greenhouse and field trials

Authors

  • Reena Josephine CM Department of Life Sciences, Kristu Jayanti College (Autonomous), K. Narayanapura, Kothanur (PO), Bengaluru-560077
  • Jibu Thomas 2Algae Biomass Research Laboratory, Department of Biosciences and Technology, Karunya Institute of Technology and Sciences, Coimbatore-641114

DOI:

https://doi.org/10.5530/ctbp.2021.3s.34

Keywords:

Pseudomonas indoloxydans, Seed bacterization, Talc, Lignite, Agriculture

Abstract

A rhizospheric bacterium belonging to the genus Pseudomonas isolated from the rhizosphere of maize was evaluated for the plant growth promoting and biocontrol traits. The strain was subjected to the different PGP and biocontrol traits such as ammonia, IAA, siderophores, phosphate solubilisation, ACC deaminase, HCN production, cellulase, pectinase and chitinase activity. 16S rRNA sequencing showed maximum homology with the strain Pseudomonas indoloxydans IPL-1(NR115922). In vivo plant growth promotion assay with the strains on maize seedlings showed a significant increase in the biometric parameters with respect to the number of shoots (32%) and roots (27%) and its fresh weight (20%) and dry weight (54%). Different formulations of the strain tested in fields revealed that the maize plants treated with the talc and lignite formulations showed a considerable increase in the growth of maize when compared to the plants without any treatment. The study concluded that the rhizosphere strains Pseudomonas indoloxydans (F3- 47) could be a potential plant growth promoter for future exploration in agriculture.

Effect of the inoculation of the different bioformulations on the yield parameters of maize Data represents mean value±S.D

Downloads

Published

2021-11-01

How to Cite

CM, R. J., & Thomas, J. . (2021). Rhizosphere competent Pseudomonas indoloxydans (F3-47) as a plant growth promoter and enhancer of Zea mays L. under greenhouse and field trials. Current Trends in Biotechnology and Pharmacy, 15(5), 411–418. https://doi.org/10.5530/ctbp.2021.3s.34